Dishman Carbogen Amcis Ltd — earnings calls

Dishman Carbogen Amcis reported a 4% year-on-year decline in Q1 FY27 revenue to INR 6,776 million, which management attributed largely to an order postponed to the second half of the year. EBITDA fell to INR 600 million from INR 1,406 million in the prior year quarter, with the CDMO segment margin dropping to 6.3% from 17.9%. Management discussed an in-progress plan to raise up to CHF 200 million via the promoter entity to refinance high-cost Indian debt, and outlined expectations of single-digit revenue growth for the full year with EBITDA margins similar to the prior year.

Dishman Carbogen Amcis reported Q4 FY26 revenue of INR 851 crores, up close to 19% year-on-year, with EBITDA margin at 19.1% for the quarter. For the full year, revenue rose to INR 2,932 crores from INR 2,711 crores, and EBITDA margin improved to 19.3% from 17.3% in FY25. Management discussed a proposed related-party external commercial borrowing to refinance high-cost India debt, growth in the Vitamin D analogs and ADC linker-payload businesses, and plans for India capacity ramp-up.